1. Simplified glycaemic management for patients with type 2 diabetes admitted for acute decompensated heart failure using linagliptin
- Author
-
Juan Ignacio Rico-Robles, Julio Osuna-Sánchez, J.P. Lara, Ricardo Gómez-Huelgas, Luis M. Pérez-Belmonte, and Michele Ricci
- Subjects
medicine.medical_specialty ,Acute decompensated heart failure ,business.industry ,Insulin ,medicine.medical_treatment ,General Medicine ,Type 2 diabetes ,medicine.disease ,Linagliptin ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Internal medicine ,Heart failure ,Propensity score matching ,medicine ,Decompensation ,030212 general & internal medicine ,business ,medicine.drug - Abstract
Introduction and objectives Hyperglycaemia in hospitalized patients with type 2 diabetes is preferably managed with insulin. We aimed to analyse the glycaemic efficacy, treatment simplicity, and safety of our hospital's antihyperglycemic regimens (linagliptin-basal insulin versus basal-bolus insulin) in patients with type 2 diabetes admitted for heart failure decompensation. Patients and methods In this real-world study, we included patients with mild-to-moderate hyperglycaemia managed with our antihyperglycemic regimens between 2016 and 2018. To match patients who started one of the regimens, a propensity matching analysis was used. Results After propensity matching, 146 patients were included in each group. There were no differences in mean blood glucose levels (163.6 ± 21.2 vs 159.6 ± 19.2 mg/dl, p = .210). Patients on the linagliptin-basal insulin regimen had a lower total number of hypoglycaemic episodes (36 vs 64, p Conclusions Linagliptin-basal insulin was a safe, simple, and efficacious regimen and could be considered standard of care for these vulnerable, high complex patients to simplify in-hospital management.
- Published
- 2022